Remove Capital Remove Develop Remove Thousand Oaks
article thumbnail

Thousand Oaks Biopharmaceuticals Gets $45M In Series A For Biotech Manufacturing

socalTECH

Thousand Oaks- and Shanghai-based Thousand Oaks Biopharmaceuticals , a new contract manufacturing organization fort he biotech industry, said it has received $45M in a Series A financing round. The company's Chairman is Shun Luo, Ph.D.,

article thumbnail

Xirrus Raises $10M More

socalTECH

Thousand Oaks-based wireless hardware provider Xirrus has raised yet another $10M in funding, according to a regulatory filing from the company Monday. Xirrus develops specialized, Wi-Fi hotspots specifically aimed at high density and high performance installations, such as campuses and public areas. Venture Partners.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Atara Biotherapeutics Gets $38.5M

socalTECH

Thousand Oaks-based biopharmaceuticals startup Atara Biotherapeutics announced this morning that it has raised $38.5M in a Series B funding round, for its efforts to develop treatments for patients with end-stage renal disease. atara biotherapeutics venture capital renal disease lifescience amgen' READ MORE>>.

article thumbnail

Amgen Acquires Firm For $1 Billion

socalTECH

Thousand Oaks-based biotech giant Amgen said Monday afternoon that it is acquiring Biovex , a Woburn, Massachusetts-based developer of treatments for melanoma and head and neck cancer. BioVex develops OncoVEX, a novel oncolytic vaccine in Phase 3 clinical development. READ MORE>>.

article thumbnail

Amgen Backs Therapeutic Antibody Firm

socalTECH

Thousand Oaks-based biotech giant Amgen has backed a developer of therapeutic antibodies, via its venture capital arm, Amgen Ventures. Theraclone is developing therapeutic antibodies for treating infectious disease and cancer. READ MORE>>.

article thumbnail

Xirrus Raises $10.1M More

socalTECH

Xirrus , the wireless hardware provider based in Thousand Oaks, has just raised $10.1M Xirrus, which is backed by August Capital, Canaan Partners, InterWest Partners, QuestMark Partners, and US Venture Partners, last announced a funding round back in September. in a funding round, part of an ongoing $11.0M

article thumbnail

Amgen Buys KAI Pharmaceuticals

socalTECH

Thousand Oaks-based biotech giant Amgen said this morning that it has agreed to buy KAI Pharmaceuticals , a developer of treatments for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis, for $315M in cash. KAI Pharmaceuticals is based in South San Francisco. READ MORE>>.